Virax Biolabs Group Limited

VRAX | Healthcare | NASDAQ
$0.51
-0.03 (-5.90%)

Key Metrics

Market Cap
$2.21M
P/E Ratio
-0.31
EPS
$-1.62
Beta
N/A
Dividend Yield
N/A
ROE
-84.53%
Current Ratio
7.27

Company Information

Industry
Biotechnology

About Virax Biolabs Group Limited

Virax Biolabs Group Limited a biotechnology company sells distributes and markets diagnostics test kits and medtech and PPE products for the prevention detection diagnosis and risk management of viral diseases in the field of immunology The company provides rapid antibody IgCIgM tests antigen tests polymerase chain reaction rapid tests and neutralizing antibody tests under the ViraxClear brand name and medtech and PPE products such as employee protection equipment products under the ViraxCare brand name as well as infrared thermometers pulse oximeters masks gloves and other PPE products It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines In addition the company operates an online platform that sells ViraxClear and ViraxCare products It serves clinics pharmacies laboratories hospitals and other groups as well as corporations employees individual consumers hospital systems and public and private institutions The company operates in Europe South America the Asia Pacific SubSaharan Africa and internationally The company was formerly known as Virax Biolabs Cayman Limited and changed its name to Virax Biolabs Group Limited in September 2021 Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London the United Kingdom

Financial Ratios (TTM)

Gross Margin
-838.21%
Operating Margin
-97,344.80%
Net Margin
-95,739.20%
ROA
-94.31%
Price to Book
0.39
Price to Sales
349.77